On Monday, analysts at Morgan Stanley reiterated their Overweight rating on Gilead Sciences, Inc. (NASDAQ:GILD), while ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory ...

TWN calls for urgent need of stronger scrutiny in granting patents to avoid evergreening: Our Bureau, New Delhi Tuesday, June 3, 2025, 08:00 Hrs [IST] Third World Network (TWN), a ...

Lenacapavir works to both treat and prevent HIV, making it a promising drug should it be approved by the FDA later this month.

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Reclaim your full access. Click below to renew. The increased government borrowing is attributed to slow growth in tax revenues and a surge in government expenditure driven by supplementary budget ...

The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the launch of a groundbreaking grant program in partnership with Gilead Sciences aimed at advancing the field of ...

The administration of Donald Trump has reportedly terminated funding for several HIV vaccine research programs.

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...

The Trump administration's decision to halt a $258 million HIV vaccine research program has sparked widespread concern. This ...